Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived anti-BCMA CAR T cells
- Development stage
- Unknown
- Lead developer
- Shaanxi People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord blood-derived anti-BCMA CAR T cells is an investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy being developed by Shaanxi People's Hospital for the treatment of relapsed or refractory multiple myeloma. This therapy utilizes T cells harvested from allogeneic umbilical cord blood (UCB), which are genetically engineered to express a CAR targeting B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells. The use of UCB as a cell source offers a potential "off-the-shelf" alternative to autologous CAR-T therapies, potentially reducing the risk of graft-versus-host disease (GvHD) due to the immunological immaturity of neonatal T cells. The therapy is designed to selectively bind to and eliminate BCMA-positive myeloma cells through T-cell mediated cytotoxicity.
- Other names
- umbilical cord blood-derived BCMA-targeted CAR-T cellsUCB-derived anti-BCMA CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on umbilical cord blood-derived anti-BCMA CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived anti-BCMA CAR T cells.